暂停nex-z三期临床试验的患者给药和筛查工作 Intellia Therapeutics(NTLA.US)暴跌超45%

Core Viewpoint - Intellia Therapeutics experienced a significant stock drop of over 45%, closing at $13.90, following the suspension of two Phase 3 clinical trials related to its drug nex-z due to safety concerns [1] Group 1: Clinical Trials - The company has paused patient dosing and screening for two Phase 3 trials targeting patients with transthyretin amyloidosis with cardiomyopathy and polyneuropathy [1] - The suspension was prompted by a report of a patient experiencing grade 4 liver transaminase elevation and increased total bilirubin after treatment [1] - The affected patient has been hospitalized and is receiving medical intervention [1] Group 2: Company Response - Intellia is consulting with experts and considering potential risk mitigation strategies [1] - The company is also in communication with regulatory agencies, aiming to resume trial recruitment as soon as appropriate [1]